Marc Scherlinger

OX40L/OX40 axis impairs follicular and natural Treg function in human SLE

C. Jacquemin, Jean‐François Augusto, Marc Scherlinger et al. · JCI Insight · 2018 · 82 citations · Full text

Ox40l/ox40 Axis, T-regulatory Cell, Immunology +19

Switching from originator infliximab to biosimilar CT-P13 in real-life: The weight of patient acceptance

Marc Scherlinger, Vincent Germain, Céline Labadie et al. · Joint Bone Spine · 2017 · 81 citations

Clinical Effectiveness, Clinical Translation, Patient Safety +8

Refining “Long-COVID” by a Prospective Multimodal Evaluation of Patients with Long-Term Symptoms Attributed to SARS-CoV-2 Infection

Marc Scherlinger, Renaud Felten, Floriane Gallais et al. · Infectious Diseases and Therapy · 2021 · 77 citations · Full text

Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4)

Marc Scherlinger, Emmanuel Langlois, Vincent Germain et al. · Seminars in Arthritis and Rheumatism · 2018 · 61 citations · Full text

Sociological Factors, Innovation Adoption, Management +5

Characteristics and clinical outcomes after treatment of a national cohort of PCR-positive Lyme arthritis

Antoine Grillon, Marc Scherlinger, Pierre-Hugues Boyer et al. · Seminars in Arthritis and Rheumatism · 2018 · 55 citations · Full text

Rheumatology, Epidemiology, Autoimmune Disease +12